Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.37 |
| ▸ | MDH1 | P40925 | 1/20 | 0.37 |
| ▸ | MDH2 | P40926 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12998285 | 0.77 | PPARA (0.53) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL6357197 | 0.76 | PPARA (0.51) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL13757723 | 0.73 | PPARA (0.71) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3903999 | 0.72 | PPARA (0.76) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL13270947 | 0.72 | PPARA (0.66) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL22192257 | 0.71 | CYP1A2 (0.61) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL7977777 | 0.70 | PPARA (0.68) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3823703 | 0.70 | PPARA (0.71) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL8794052 | 0.70 | PPARA (0.71) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL1154731 | 0.70 | PPARA (0.71) | PPARAABCB11CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154062-A1 | Substituted chiral allosteric hemoglobin modifiers | ALLOS THERAPEUTICS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-6894185-B2 | Substituted chiral allosteric hemoglobin modifiers | Allós Therapeutics, Inc. (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1206442-A4 | SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS | UNIV VIRGINIA COMMONWEALTH (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030130523-A1 | Substituted chiral allosteric hemoglobin modifiers | ABRAHAM DONALD J (US) | 2003-07-10 | — | — | US | disclosed |
| US-6486342-B1 | Substituted chiral allosteric hemoglobin modifiers | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-11-26 | — | — | US | disclosed |
| EP-1206442-A1 | SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001014316-A1 | SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130523-A1 | Substituted chiral allosteric hemoglobin modifiers | HBZ, HBB, HBG2 | PPARA 1742/4885ABCB11 4788/4885CYP1A2 3569/4885 |
| US-20050154062-A1 | Substituted chiral allosteric hemoglobin modifiers | HBZ, HBB, HBG2 | PPARA 1742/4885ABCB11 4788/4885CYP1A2 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.